Dava pharmaceuticals is a subsidiary of Endo International plc, an American Irish-domiciled generics and specialty branded pharmaceutical company. In 2014, Endo International reached a $575 million agreement to acquire the previously privately-held company specializing in generic pharmaceuticals.
Dava pharmaceuticals supplies several formulations of Xanax the most popular being the S 90 3 green bar which contains 2 mg of the active ingredient (alprazolam) and the S 901 yellow which contains 0.5 mg. Dava Pharmaceuticals Xanax is prescribed to treat generalized anxiety disorder (GAD), panic disorders, and insomnia. It is extremely addictive when used long-term, making addiction and abuse a serious concern.
Along with other brands, Dava pharmaceuticals Xanax is among the top most prescribed psychiatric medication in the United States. However as with every brand, tolerance to Dava Xanax develops quickly, requiring the user to take more of the drug to achieve the desired effects. Someone with a Xanax addiction may take up to 20 or 30 pills per day. If the user decides to stop taking Xanax, they may experience withdrawal effects such as anxiety, restlessness, insomnia, and tremors.
Dava pharmaceuticals Xanax is a controlled substance. The active ingredient alprazolam is a Schedule IV controlled substance, which is less likely to be abused than a Schedule III drug, but it still has the potential for abuse. The drug can become addictive, and it’s especially dangerous when prescribed with opioids.
Is Dava Pharmaceuticals Xanax Discontinued?
No, Dava Pharmaceuticals brands of Xanax are still in production, despite the illegal production of fake version of their popular S 90 3 hulk Xanax. However, following the reported contamination of the S 901, The Food and Drug Administration announced a nationwide recall of a batch of S 901 due to possible presence of a foreign substance. The affected batch of 0.5-milligram doses was distributed in the United States in 500-tablet bottles in July and August, with an expiration date of September 2020. Jeremy Kahn, a spokesman for the F.D.A., said that patients who filled prescriptions for the drug during those months should consult their pharmacist.